
63.87 Delayed Data As of Jul 01 | ![]() Today’s Change | 42.51 Today|||52-Week Range 163.00 | -15.72% Year-to-Date |
The 23 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 112.00, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +75.36% increase from the last price of 63.87.
The current consensus among 28 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.